Abeona Therapeutics Inc ABEO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:40 AM EDT
7.57quote price arrow up+0.04 (+0.53%)
Volume
17,584
52 week range
2.83 - 9.01
Loading...
  • Open7.50
  • Day High7.57
  • Day Low7.43
  • Prev Close7.53
  • 52 Week High9.01
  • 52 Week High Date03/06/24
  • 52 Week Low2.83
  • 52 Week Low Date08/08/23

Key Stats

  • Market Cap207.078M
  • Shares Out27.36M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.43
  • YTD % Change50.3

KEY STATS

  • Open7.50
  • Day High7.57
  • Day Low7.43
  • Prev Close7.53
  • 52 Week High9.01
  • 52 Week High Date03/06/24
  • 52 Week Low2.83
  • 52 Week Low Date08/08/23
  • Market Cap207.078M
  • Shares Out27.36M
  • 10 Day Average Volume0.24M
  • Dividend-
  • Dividend Yield-
  • Beta1.43
  • YTD % Change50.3

RATIOS/PROFITABILITY

  • EPS (TTM)-2.59
  • P/E (TTM)-2.93
  • Fwd P/E (NTM)-3.58
  • EBITDA (TTM)-45.864M
  • ROE (TTM)-260.60%
  • Revenue (TTM)3.50M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,548.23%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/09/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Abeona Therapeutics Inc

 

Profile

MORE
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP)...
Michael Amoroso
Chairman of the Board
Vishwas Seshadri Ph.D.
President, Chief Executive Officer, Director
Joseph Vazzano CPA
Chief Financial Officer
Brendan O Malley J.D., Ph.D.
General Counsel
Address
6555 CARNEGIE AVE, 4TH FLOOR
Cleveland, OH
44103
United States